Skip to main content
DIACEUTICS PLC logo

DIACEUTICS PLC — Investor Relations & Filings

Ticker · DXRX ISIN · GB00BJQTGV64 LEI · 213800VEWQBB39ZB8J81 IL Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 277 across all filing types
Latest filing 2025-05-15 Director's Dealing
Country GB United Kingdom
Listing IL DXRX

About DIACEUTICS PLC

https://www.diaceutics.com/

Diaceutics PLC is a data analytics and end-to-end services provider focused on the development and commercialization of precision medicine diagnostics. The company supports pharmaceutical and biotech clients by providing solutions to improve the diagnostic testing ecosystem, aiming to ensure patients receive the correct personalized treatment. Its primary offering is DXRX, The Diagnostic Network®, a diagnostic commercialization platform for precision medicine. DXRX facilitates collaboration among stakeholders, including laboratories and pharmaceutical companies, in a secure marketplace and provides access to real-world diagnostic testing data. This integrated platform is designed to streamline the launch and adoption of new precision medicines.

Recent filings

Filing Released Lang Actions
Transaction by Persons Closely Associated to PDMRs
Director's Dealing Classification · 98% confidence The document is a formal notification titled 'Notification of Transaction by Persons Closely Associated ("PCAs") to Persons Discharging Managerial Responsibilities ("PDMRs")' and includes structured data tables referencing MAR (Market Abuse Regulation) and Article 19(1) notifications. It details the sale of ordinary shares by an associate of a director (Peter Keeling) and subsequently includes a 'TR-1: Standard form for notification of major holdings' which reports a change in the combined shareholding percentage (from 18.60% to 17.98%). This content specifically relates to insider transactions by directors/executives and changes in significant share ownership thresholds. The most specific category for director/executive share transactions is 'Director's Dealing' (DIRS). While it also touches upon major shareholding notification (MRQ), the primary focus and structure revolve around the PDMR transaction disclosure (TR-1 form), making DIRS the most appropriate primary classification. The document is a direct filing/report, not an announcement of a report (RPA).
2025-05-15 English
FY 2024 Results - Strong Revenue Growth
Earnings Release Classification · 100% confidence The document is an official announcement from Diaceutics PLC regarding its 'FY 2024 Results'. It contains key financial highlights, commercial performance metrics, and management commentary for the fiscal year ended December 31, 2024. While it includes a 'Chair's review' and detailed financial tables, it is structured as a press release (indicated by the RNS header and contact information) providing the initial disclosure of annual results. According to the filing definitions, this is an Earnings Release (ER) as it serves as the initial announcement of periodical financial results. FY 2024
2025-05-13 English
PDMR Shareholding/Share Incentive Plan and TVR
Director's Dealing Classification · 100% confidence The document is an RNS announcement (RNS Number : 6824G) dated April 29, 2025. The content explicitly details share purchases and matched share awards by Persons Discharging Managerial Responsibilities (PDMRs) under the company's Share Incentive Plan (SIP Schemes). This type of filing, reporting personal share transactions by directors and executives, directly corresponds to the definition of Director's Dealing. The presence of the standardized table format for 'Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014' confirms this classification. Therefore, the appropriate code is DIRS.
2025-04-29 English
Notice of Results
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) from Diaceutics PLC titled 'Notice of Results & Presentations'. It informs the market that the company will announce its audited final results on a future date (13 May 2025) and provides details for upcoming analyst and investor presentations. Per the 'Menu vs Meal' rule, this is an announcement regarding the publication of a report, not the report itself, making it a Report Publication Announcement (RPA).
2025-04-29 English
Block Listing Return
Share Issue/Capital Change Classification · 100% confidence The document is a 'Block Listing Return' filed by Diaceutics PLC. This type of filing is a standard regulatory requirement under the AIM Rules for Companies to report on the issuance of shares under employee share schemes (SIP and ESOP). It details the number of securities issued, the balance remaining, and the total number of securities in issue. This falls under the category of share capital changes and issuance reporting.
2025-04-07 English
PDMR Shareholding/Share Incentive Plan and TVR
Director's Dealing Classification · 100% confidence The document is a formal notification of share transactions by Persons Discharging Managerial Responsibilities (PDMRs) at Diaceutics PLC. It explicitly includes the 'Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014' tables, which are standard for reporting insider dealings. The content details share purchases and matched share awards under an employee incentive plan. This aligns perfectly with the definition of 'Director's Dealing' (DIRS).
2025-04-03 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.